Schedule 13D ownership disclosure
Fennec Pharmaceuticals Inc
Security class unavailable · CUSIP: 31447P100
Event date: 2017-12-12
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 3,225,694
- Percent of class
- 17.7000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-17-013418
- Form type
- SC 13D
- Filer
- Essetifin SPA
- CIK
- CIK 1092601
- Filed
- Dec 19, 2017
- Reporting period
- Dec 12, 2017
- Description
- Schedule 13D beneficial ownership